Elsa Anes

Lisbon, 1649003, Portugal

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Genetic interference of distinctive Mycobacterium tuberculosis peptidoglycan modifications enhances β-lactam susceptibility and reveals expression-sensitive host immune dynamics.

Genetic interference of distinctive Mycobacterium tuberculosis peptidoglycan modifications enhances β-lactam susceptibility and reveals expression-sensitive host immune dynamics.

Journal: Scientific reports
Published: February 18, 2026

Effects of CwlM, a peptidoglycan synthesis regulator, on beta-lactam tolerance and host-pathogen interactions.

Effects of CwlM, a peptidoglycan synthesis regulator, on beta-lactam tolerance and host-pathogen interactions.

Journal: BMC microbiology
Published: July 09, 2025

Editorial: Rising stars in tuberculosis.

Editorial: Rising stars in tuberculosis.

Journal: Frontiers in tuberculosis
Published: May 26, 2025

Host-Directed Therapies Based on Protease Inhibitors to Control Mycobacterium tuberculosis and HIV Coinfection.

Host-Directed Therapies Based on Protease Inhibitors to Control Mycobacterium tuberculosis and HIV Coinfection.

Journal: Microorganisms
Published: March 14, 2025

Editorial: Immune responses to MTB infection in people living with HIV.

Editorial: Immune responses to MTB infection in people living with HIV.

Journal: Frontiers in immunology
Published: November 05, 2024

Cystatin F Depletion in Mycobacterium tuberculosis-Infected Macrophages Improves Cathepsin C/Granzyme B-Driven Cytotoxic Effects on HIV-Infected Cells during Coinfection.

Cystatin F Depletion in Mycobacterium tuberculosis-Infected Macrophages Improves Cathepsin C/Granzyme B-Driven Cytotoxic Effects on HIV-Infected Cells during Coinfection.

Journal: International journal of molecular sciences
Published: July 13, 2024

Role of Type I Interferons during Mycobacterium tuberculosis and HIV Infections.

Role of Type I Interferons during Mycobacterium tuberculosis and HIV Infections.

Journal: Biomolecules
Published: June 18, 2024

Synthesis, Activity, Toxicity, and In Silico Studies of New Antimycobacterial N-Alkyl Nitrobenzamides.

Synthesis, Activity, Toxicity, and In Silico Studies of New Antimycobacterial N-Alkyl Nitrobenzamides.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 24, 2024

Development of New Drugs to Treat Tuberculosis Based on the Dinitrobenzamide Scaffold.

Development of New Drugs to Treat Tuberculosis Based on the Dinitrobenzamide Scaffold.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 12, 2024

Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.

Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.

Journal: Antimicrobial agents and chemotherapy
Published: February 27, 2024

Unravelling the triad of neuroinvasion, neurodissemination, and neuroinflammation of human immunodeficiency virus type 1 in the central nervous system.

Unravelling the triad of neuroinvasion, neurodissemination, and neuroinflammation of human immunodeficiency virus type 1 in the central nervous system.

Journal: Reviews in medical virology
Published: November 22, 2023

Human immunodeficiency virus transmission-Mechanisms underlying the cell-to-cell spread of human immunodeficiency virus.

Human immunodeficiency virus transmission-Mechanisms underlying the cell-to-cell spread of human immunodeficiency virus.

Journal: Reviews in medical virology
Published: June 29, 2023
Showing 1-12 of 41

Last Updated: 09/26/2026